FORMYCON AG (FYB.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:FYB - DE000A1EWVY8 - Common Stock
24.85 EUR
+0.45 (+1.84%)
Taking everything into account, FYB scores 3 out of 10 in our fundamental rating. FYB was compared to 82 industry peers in the Biotechnology industry. FYB may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, FYB is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year FYB has reported negative net income.
FYB had a positive operating cash flow in the past year.
In multiple years FYB reported negative net income over the last 5 years.
FYB had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
FYB has a Return On Assets (-22.86%) which is comparable to the rest of the industry.
FYB has a Return On Equity of -41.58%. This is comparable to the rest of the industry: FYB outperforms 58.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.86% | ||
| ROE | -41.58% | ||
| ROIC | N/A |
ROA(3y)-1.19%
ROA(5y)-6.14%
ROE(3y)-0.68%
ROE(5y)-7.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for FYB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FYB has been increased compared to 1 year ago.
FYB has more shares outstanding than it did 5 years ago.
FYB has a better debt/assets ratio than last year.
2.2 Solvency
FYB has an Altman-Z score of 1.47. This is a bad value and indicates that FYB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.47, FYB is in the better half of the industry, outperforming 62.20% of the companies in the same industry.
A Debt/Equity ratio of 0.02 indicates that FYB is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.02, FYB is doing good in the industry, outperforming 68.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.47 |
ROIC/WACCN/A
WACC7.13%
2.3 Liquidity
FYB has a Current Ratio of 1.54. This is a normal value and indicates that FYB is financially healthy and should not expect problems in meeting its short term obligations.
FYB has a Current ratio of 1.54. This is in the lower half of the industry: FYB underperforms 60.98% of its industry peers.
FYB has a Quick Ratio of 1.51. This is a normal value and indicates that FYB is financially healthy and should not expect problems in meeting its short term obligations.
FYB has a Quick ratio (1.51) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.51 |
3. Growth
3.1 Past
The earnings per share for FYB have decreased strongly by -339.98% in the last year.
FYB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.84%.
FYB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.48% yearly.
EPS 1Y (TTM)-339.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425.42%
Revenue 1Y (TTM)-14.84%
Revenue growth 3Y23.92%
Revenue growth 5Y15.48%
Sales Q2Q%0.03%
3.2 Future
Based on estimates for the next years, FYB will show a very strong growth in Earnings Per Share. The EPS will grow by 49.56% on average per year.
FYB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.88% yearly.
EPS Next Y-86.84%
EPS Next 2Y31.17%
EPS Next 3Y49.56%
EPS Next 5YN/A
Revenue Next Year-8%
Revenue Next 2Y22.8%
Revenue Next 3Y31.02%
Revenue Next 5Y21.88%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
FYB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FYB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
92.68% of the companies in the same industry are more expensive than FYB, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 3.69 |
4.3 Compensation for Growth
A more expensive valuation may be justified as FYB's earnings are expected to grow with 49.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.17%
EPS Next 3Y49.56%
5. Dividend
5.1 Amount
FYB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:FYB (12/23/2025, 7:00:00 PM)
24.85
+0.45 (+1.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.19%
Inst Owner ChangeN/A
Ins Owners3.28%
Ins Owner ChangeN/A
Market Cap439.10M
Revenue(TTM)51.78M
Net Income(TTM)-169.77M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)13.28%
Min Revenue beat(2)-63.69%
Max Revenue beat(2)90.24%
Revenue beat(4)2
Avg Revenue beat(4)18.75%
Min Revenue beat(4)-63.69%
Max Revenue beat(4)90.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.84%
PT rev (3m)-4.84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-121.05%
EPS NY rev (1m)16.98%
EPS NY rev (3m)0.56%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-50%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)1.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 8.48 | ||
| P/FCF | N/A | ||
| P/OCF | 29.75 | ||
| P/B | 1.08 | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.69 |
EPS(TTM)-9.6
EYN/A
EPS(NY)-0.27
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)0.84
OCFY3.36%
SpS2.93
BVpS23.11
TBVpS-2.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.86% | ||
| ROE | -41.58% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-1.19%
ROA(5y)-6.14%
ROE(3y)-0.68%
ROE(5y)-7.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.08 | ||
| Cap/Depr | 24.47% | ||
| Cap/Sales | 71.59% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 12.89% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.51 | ||
| Altman-Z | 1.47 |
F-Score3
WACC7.13%
ROIC/WACCN/A
Cap/Depr(3y)860.64%
Cap/Depr(5y)536.06%
Cap/Sales(3y)44.41%
Cap/Sales(5y)27.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-339.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-425.42%
EPS Next Y-86.84%
EPS Next 2Y31.17%
EPS Next 3Y49.56%
EPS Next 5YN/A
Revenue 1Y (TTM)-14.84%
Revenue growth 3Y23.92%
Revenue growth 5Y15.48%
Sales Q2Q%0.03%
Revenue Next Year-8%
Revenue Next 2Y22.8%
Revenue Next 3Y31.02%
Revenue Next 5Y21.88%
EBIT growth 1Y-49.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102.17%
EBIT Next 3Y115.87%
EBIT Next 5Y71.98%
FCF growth 1Y58.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y186.39%
OCF growth 3YN/A
OCF growth 5YN/A
FORMYCON AG / FYB.DE FAQ
What is the ChartMill fundamental rating of FORMYCON AG (FYB.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to FYB.DE.
Can you provide the valuation status for FORMYCON AG?
ChartMill assigns a valuation rating of 2 / 10 to FORMYCON AG (FYB.DE). This can be considered as Overvalued.
What is the profitability of FYB stock?
FORMYCON AG (FYB.DE) has a profitability rating of 1 / 10.
What is the financial health of FORMYCON AG (FYB.DE) stock?
The financial health rating of FORMYCON AG (FYB.DE) is 3 / 10.
What is the earnings growth outlook for FORMYCON AG?
The Earnings per Share (EPS) of FORMYCON AG (FYB.DE) is expected to decline by -86.84% in the next year.